Castleark Management LLC Takes Position in Phibro Animal Health Corporation $PAHC

Castleark Management LLC purchased a new position in Phibro Animal Health Corporation (NASDAQ:PAHC) during the first quarter, HoldingsChannel reports. The firm purchased 142,900 shares of the company’s stock, valued at approximately $7,904,000.

Several other institutional investors also recently added to or reduced their stakes in the stock. KBC Group NV purchased a new position in Phibro Animal Health in the 1st quarter worth about $29,000. 1620 Investment Advisors Inc. boosted its position in Phibro Animal Health by 77.4% in the 4th quarter. 1620 Investment Advisors Inc. now owns 676 shares of the company’s stock valued at $25,000 after buying an additional 295 shares during the period. Farther Finance Advisors LLC grew its stake in Phibro Animal Health by 113.2% in the 4th quarter. Farther Finance Advisors LLC now owns 727 shares of the company’s stock worth $27,000 after acquiring an additional 386 shares in the last quarter. Rothschild Investment LLC grew its stake in Phibro Animal Health by 2,500.0% in the 4th quarter. Rothschild Investment LLC now owns 1,040 shares of the company’s stock worth $39,000 after acquiring an additional 1,000 shares in the last quarter. Finally, iSAM Funds UK Ltd purchased a new position in shares of Phibro Animal Health during the third quarter worth approximately $61,000. Hedge funds and other institutional investors own 99.34% of the company’s stock.

Analysts Set New Price Targets

PAHC has been the subject of several research analyst reports. Wall Street Zen downgraded shares of Phibro Animal Health from a “strong-buy” rating to a “buy” rating in a research note on Saturday, May 9th. Zacks Research downgraded Phibro Animal Health from a “strong-buy” rating to a “hold” rating in a report on Thursday, May 21st. Citigroup decreased their target price on Phibro Animal Health from $62.00 to $44.00 and set a “neutral” rating for the company in a research report on Thursday, May 14th. Finally, Weiss Ratings cut Phibro Animal Health from a “buy (b-)” rating to a “hold (c+)” rating in a report on Monday, June 15th. One equities research analyst has rated the stock with a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Phibro Animal Health presently has a consensus rating of “Hold” and an average target price of $42.50.

Phibro Animal Health Stock Down 0.0%

Shares of Phibro Animal Health stock opened at $34.03 on Monday. The company has a debt-to-equity ratio of 1.97, a current ratio of 3.17 and a quick ratio of 1.26. The stock has a market cap of $1.38 billion, a price-to-earnings ratio of 14.61, a PEG ratio of 0.48 and a beta of 0.46. The firm’s 50-day moving average is $32.45 and its two-hundred day moving average is $43.29. Phibro Animal Health Corporation has a 1 year low of $25.58 and a 1 year high of $60.08.

Phibro Animal Health (NASDAQ:PAHC) last posted its quarterly earnings results on Wednesday, May 6th. The company reported $0.76 EPS for the quarter, beating the consensus estimate of $0.72 by $0.04. Phibro Animal Health had a net margin of 6.35% and a return on equity of 37.14%. The business had revenue of $383.54 million during the quarter, compared to analyst estimates of $367.02 million. Phibro Animal Health has set its FY 2026 guidance at 2.980-3.100 EPS. As a group, research analysts expect that Phibro Animal Health Corporation will post 3.08 earnings per share for the current fiscal year.

Phibro Animal Health Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Wednesday, June 24th. Investors of record on Wednesday, June 3rd were issued a dividend of $0.12 per share. This represents a $0.48 annualized dividend and a yield of 1.4%. The ex-dividend date of this dividend was Wednesday, June 3rd. Phibro Animal Health’s dividend payout ratio (DPR) is presently 20.60%.

Insider Buying and Selling

In related news, CEO Jack Bendheim sold 7,040 shares of the business’s stock in a transaction that occurred on Tuesday, May 5th. The shares were sold at an average price of $55.80, for a total value of $392,832.00. Following the completion of the transaction, the chief executive officer owned 67,720 shares of the company’s stock, valued at $3,778,776. The trade was a 9.42% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 25,648 shares of company stock valued at $1,377,432 over the last ninety days. Insiders own 50.13% of the company’s stock.

Phibro Animal Health Company Profile

Phibro Animal Health Corporation (NASDAQ: PAHC) is a diversified global animal health and mineral nutrition company headquartered in Teaneck, New Jersey. The company develops, manufactures and markets a broad range of pharmaceutical, mineral nutrition and performance products designed to support the health and productivity of livestock, companion animals and aquaculture species. Phibro’s portfolio includes vaccines, anti-infective therapies, coccidiostats, disinfectants, premix minerals and specialty feed additives aimed at enhancing growth, immunity and overall animal well-being.

The company operates through three principal business segments: Animal Health, Mineral Nutrition and Performance Products.